[New oral quinolone compounds in chronic bronchitis]

Area of Science:

• Pharmacology
• Infectious Diseases
• Respiratory Medicine

Background:

• Acute purulent exacerbations of chronic bronchitis are often associated with bacterial infections.
• New quinolone antimicrobial agents offer potential treatment options.

Purpose of the Study:

• To evaluate the clinical, microbiological, and pharmacokinetic profiles of four new quinolone antimicrobial agents.
• To compare the efficacy and safety of enoxacin, pefloxacin, ciprofloxacin, and ofloxacin in treating chronic bronchitis exacerbations.

Main Methods:

• A study involving 186 patients hospitalized for acute purulent exacerbations of chronic bronchitis.
• Patients were treated with enoxacin, pefloxacin, ciprofloxacin, or ofloxacin.
• Clinical outcomes, microbiological data, and pharmacokinetic parameters were assessed.

Main Results:

• Haemophilus influenzae and Branhamella catarrhalis showed high sensitivity to quinolones, with sputum concentrations exceeding minimum inhibitory concentrations (MICs).
• Pseudomonas aeruginosa and Streptococcus pneumoniae exhibited lower sensitivity, with higher MICs and some treatment failures.
• Ofloxacin yielded the best clinical results, even with once-daily dosing, while other quinolones showed moderate efficacy.
• Adverse drug effects, primarily gastrointestinal, were noted, particularly with enoxacin.

Conclusions:

• New quinolones are effective against common pathogens in chronic bronchitis exacerbations, but bacterial susceptibility varies.
• Ofloxacin appears to be the most effective agent among those studied, offering a favorable clinical profile.
• Further research is warranted to optimize the use of quinolones in respiratory tract infections and manage potential side effects.